Literature DB >> 24878018

Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls.

Irina Demidova1, Aleksei Barinov, Nikita Savelov, Ilia Gagarin, Viacheslav Grinevitch, Daniil Stroiakovaski, Mikhail Popov, Konstantin Laktionov, Sergei Gutorov, Alexei Smolin, Yulia Olshanskaya, Tatiana Obukhova.   

Abstract

CONTEXT: Echinoderm microtubule-associated protein-like 4 gene (EML4) and anaplastic lymphoma kinase gene (ALK) fusion was shown to be the driver of tumorigenesis in approximately 3% to 5% of patients with non-small cell lung cancer (NSCLC) and is associated with response to inhibition with crizotinib. However, no complete agreement regarding the best diagnostic test for identification of ALK rearrangements has been achieved yet.
OBJECTIVE: To investigate the concordance, sensitivity, and specificity of immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and reverse transcription-polymerase chain reaction (RT-PCR) for detection of ALK rearrangements.
DESIGN: Thirty-six prospectively tested patients with NSCLC who had adenocarcinoma and 10 ALK-positive samples were included in the study. All samples were tested by IHC (ALK1 clone, 5A4 clone, D5F3 clone), FISH (LSI ALK Break Apart and ALK FISH Probe), and multiplexed RT-PCR.
RESULTS: Immunohistochemistry staining was successful in all samples.. Clone D5F3 showed the best sensitivity and specificity of 100%; clones ALK1 and 5A4 showed sensitivities of 91% with specificity of 100%. Both FISH probes showed concordance with sensitivity and specificity of 100%. Hybridization and RT-PCR were successful in 98% and 93.4% of samples, respectively, with sensitivity of 88% and specificity of 100%. Frequent artifacts leading to misinterpretation were observed with all 3 methodologies.
CONCLUSIONS: All 3 methodologies showed good sensitivity, specificity, and concordance, when artifacts were characterized and excluded. However, all ambiguous cases have to be confirmed as ALK rearranged by at least 2 of the 3 methods.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24878018     DOI: 10.5858/arpa.2012-0762-OA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  11 in total

1.  Significance and evaluation of anaplastic lymphoma kinase by immunohistochemistry in non-small cell lung cancer.

Authors:  Shuting Ding; Nan Liu; Huanyu Zhao; Guiyang Jiang; Xiupeng Zhang; Enhua Wang
Journal:  Tumour Biol       Date:  2016-02-17

2.  Efficacy and tolerability of crizotinib in the treatment of ALK-positive, advanced non-small cell lung cancer in Chinese patients.

Authors:  Shaohua Cui; Yizhuo Zhao; Aiqin Gu; Xiaoxiao Ge; Yanyan Song; Wei Zhang; Yuqing Lou; Lili Dong; Baohui Han; Liyan Jiang
Journal:  Med Oncol       Date:  2015-05-13       Impact factor: 3.064

Review 3.  A Systematic Review of Companion Diagnostic Tests by Immunohistochemistry for the Screening of Alectinib-Treated Patients in ALK-Positive Non-Small Cell Lung Cancer.

Authors:  Sulim Kang; Jaehyun Woo; Sungmin Kim
Journal:  Diagnostics (Basel)       Date:  2022-05-23

Review 4.  Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond.

Authors:  Zeyad Kanaan; Goetz H Kloecker; Ajit Paintal; Cesar A Perez
Journal:  Onco Targets Ther       Date:  2015-04-20       Impact factor: 4.147

Review 5.  Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib.

Authors:  Fei-Yu Niu; Yi-Long Wu
Journal:  Onco Targets Ther       Date:  2015-05-02       Impact factor: 4.147

6.  Comparison of ALK status between primary and corresponding lymph node metastatic tumors in lung cancer patients.

Authors:  Qiqi Gao; Honghai Ma; Bo Wang; Yake Yao; Jianya Zhou; Jianying Zhou
Journal:  Oncotarget       Date:  2017-11-06

Review 7.  Efficacy of D5F3 IHC for detecting ALK gene rearrangement in NSCLC patients: a systematic review and meta-analysis.

Authors:  Hu Ma; Wen-Xiu Yao; Lang Huang; Su-Han Jin; Da-Hai Liu; Yuan Liu; Xu Tian; Jin-Hui Tian; Jian-Guo Zhou
Journal:  Oncotarget       Date:  2016-10-25

8.  Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry.

Authors:  Esther Conde; Ana Suárez-Gauthier; Amparo Benito; Pilar Garrido; Rosario García-Campelo; Michele Biscuola; Luis Paz-Ares; David Hardisson; Javier de Castro; M Carmen Camacho; Delvys Rodriguez-Abreu; Ihab Abdulkader; Josep Ramirez; Noemí Reguart; Marta Salido; Lara Pijuán; Edurne Arriola; Julián Sanz; Victoria Folgueras; Noemí Villanueva; Javier Gómez-Román; Manuel Hidalgo; Fernando López-Ríos
Journal:  PLoS One       Date:  2014-09-23       Impact factor: 3.240

9.  [Value of Immunohistochemical Methods in Detecting EML4-ALK Fusion Mutations: A Meta-analysis].

Authors:  Chang Liu; Lu Cai; Diansheng Zhong; Jing Wang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2016-01

Review 10.  ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients.

Authors:  Hironori Uruga; Mari Mino-Kenudson
Journal:  Pharmgenomics Pers Med       Date:  2018-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.